Rheumatoid Arthritis (RA) - Dynamic Market Forecast to 2025

Rheumatoid Arthritis (RA) - Dynamic Market Forecast to 2025


Rheumatoid Arthritis (RA) is a rapidly evolving field in which new developments are constantly influencing the market landscape. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the RA space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.


Key events covered in the Dynamic Market Forecast include -

  • Regulatory filings
  • Approval decisions
  • Pricing changes
  • Patent litigation
  • Clinical trial data announcements
  • Clinical trial failures
  • Clinical trial timeline updates
Components of the slide deck include -
  • Timeline of market-impacting events
  • Key clinical trial landscape updates
  • Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
  • Overview of updates to the forecast model based on anticipated future impact of events
  • Forward-looking events calendar listing expected key updates to the RA competitive space through June 2018
Reasons to buy
  • Recent Regulatory Events
  • Recent Commercial Events
  • Recent Clinical Events
  • Market Dynamics Shifts Towards Biosimilars in the RA Setting
  • Discontinuation of J&J’s Sirukumab for RA Creates Opportunity for Other IL-6 Inhibitors
  • Increased Competition Among the Oral JAK Inhibitors in the RA Setting

1. Dynamic Market Forecast Overview
1.1 Related Reports
1.2 Upcoming Related Reports
2. Executive Summary
2.1 Key Updates to RA Market Dynamics
2.1 Key Events in Update 10-
2.2 Clinical Trial Landscape Updates
2.3 Pipeline Landscape Updates
2.4 Market Insight on Key Events
3. Event 1: Market Dynamics Shift Towards Biosimilars
3.1 Key Updates to Biosimilar Market Dynamics
3.2 Enbrel Biosimilars
3.3 Humira Biosimilars
3.4 Remicade Biosimilars
3.5 Rituxan Biosimilars
3.6 What Do Physicians Think?
3.7 Summary/Trends
3.8 Sources
4. Event 2: Discontinuation of Sirukumab Creates Opportunity for Other IL-6 Inhibitors
4.1 Key Updates to the Anti-IL-6 Market Dynamics
4.2 J&J, sirukumab
4.3 Regeneron/Sanofi, Kevzara (sarilumab)
4.4 What Do Physicians Think?
4.5 Summary/Trends
4.6 Sources
5. Event 3: Competition Among the Oral JAK Inhibitors
5.1 Key Updates to the JAK Inhibitor Market Dynamics
5.2 Eli Lilly, Olumiant (baricitinib) 34-
5.3 AbbVie, upadacitinib
5.4 What Do Physicians Think?
5.5 Summary/Trends
5.6 Sources
6. Events Calendar
6.1 Key Events Expected to Occur H1 2018
7. Appendix
7.1 Methodology
7.2 Primary Research 44-
7.3 About the Authors 46-
7.4 About GlobalData
7.5 Contact Us
7.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook